Equine Epizootic Lymphangitis Study Guide

Overview and Clinical Importance

Epizootic lymphangitis (EL) is a chronic, contagious fungal disease affecting horses, mules, and donkeys, caused by Histoplasma capsulatum var. farciminosum. This dimorphic fungus creates characteristic pyogranulomatous skin lesions that follow lymphatic vessels, producing the pathognomonic 'cord-like' appearance.

The disease remains endemic in parts of sub-Saharan Africa, particularly Ethiopia, and poses significant welfare and economic challenges for working equids. While eradicated from most developed countries, it represents an important differential diagnosis for lymphangitis in horses.

Etiology and Pathophysiology

Causative Agent

Histoplasma capsulatum var. farciminosum is a thermally dimorphic fungus with distinct environmental and tissue forms:

• Mycelial form: Present in soil at ambient temperature (less than 35°C), produces microconidia and macroconidia
• Yeast form: Present in tissues at body temperature (37°C), characteristic spherical to pear-shaped bodies (2-5 micrometers) with double-walled appearance

Transmission and Pathogenesis

Primary transmission routes include:

• Direct contact: Contaminated wounds, abraded skin, or mucous membranes
• Mechanical transmission: Biting flies (Musca and Stomoxys species) carrying infected material
• Fomite transmission: Contaminated harnesses, grooming equipment, bedding
• Environmental exposure: Rolling on contaminated soil, inhalation of spores (rare)

Pathogenesis: Following invasion through skin wounds, the organism transforms to its yeast phase and spreads via lymphatic vessels to regional lymph nodes. The incubation period ranges from several weeks to six months, with development of pyogranulomatous inflammation characterized by macrophages containing yeast organisms.

Geographical Distribution and Epidemiology

Current endemic areas include:

• Sub-Saharan Africa: Ethiopia (most significant), Kenya, Sudan
• Historical presence: North Africa, Middle East, parts of Asia (India, Pakistan), southern Europe
• Risk factors: Warm, humid climates; altitude 1,500-2,300 meters; poor hygiene; overcrowding; mechanical injury from harnesses

Clinical Manifestations

Epizootic lymphangitis presents in four distinct clinical forms, which may occur individually or in combination:

Detailed Clinical Description

Cutaneous Form

The cutaneous form begins as a chancre-like papule that develops along superficial lymphatic vessels. Key characteristics include:

• Progressive nodule formation: Initially firm, movable nodules that become pyogranulomatous
• Ulceration pattern: Nodules ulcerate centrally, discharge thick, creamy exudate
• Cord-like appearance: Infected lymphatics become fibrosed, creating pathognomonic 'cording'
• Distribution: Forelimbs most common, followed by neck, chest, and hindlimbs

Ocular Form

Results from deposition of organisms on ocular mucous membranes by biting flies. Clinical features include:

• Initial medial canthal swelling with purulent discharge
• Conjunctival papules that progress to ulceration
• Potential lacrimal duct obstruction and fistula formation
• Secondary keratitis in severe cases

Differential Diagnosis

Several conditions can mimic epizootic lymphangitis, particularly the cutaneous form. Key differentials include:

Diagnostic Approaches

Clinical Diagnosis

Clinical diagnosis is based on characteristic features but requires laboratory confirmation:

• Cord-like appearance of superficial lymphatics
• Progressive nodule formation with ulceration
• Characteristic honey-like discharge
• Geographic/travel history to endemic areas

Laboratory Diagnosis

Microscopic Examination

Gold standard for rapid diagnosis. Sample collection and examination:

• Sample source: Aspirate pus from unruptured nodules (preferred) or fresh discharge
• Staining: Gram stain, Wright-Giemsa stain, or periodic acid-Schiff (PAS)
• Key findings: Round to oval yeast cells (2-5 micrometers) with double-walled appearance, often within macrophages
• Sensitivity: Approximately 50-70% in clinical samples

Culture

Definitive diagnosis but challenging and time-consuming:

• Media: Sabouraud dextrose agar with chloramphenicol and 2.5% glycerol (preferred)
• Incubation: 25°C for mycelial phase, may require 4-8 weeks for primary isolation
• Morphology: Yellowish to brown, convoluted, waxy colonies with cauliflower-like appearance
• Conversion: Can convert to yeast form at 37°C with 15-30% CO2

Serological Tests

Useful for epidemiological studies and detecting subclinical infections:

• Serum agglutination test: Titers greater than or equal to 1:80 considered positive
• ELISA: More sensitive than agglutination
• Limitations: Cross-reactivity possible, may reflect past exposure rather than current infection

Molecular Diagnosis

Nested PCR targeting the internal transcribed spacer (ITS) region:

• Advantages: Higher sensitivity than microscopy, can detect DNA in blood samples
• Sample types: Pus, blood, FTA cards (field-friendly)
• Clinical utility: Can detect subclinical infections, useful for epidemiological studies

Histofarcin Test

Intradermal hypersensitivity test using fungal antigen extract:

• Positive reaction indicates exposure/infection
• Used primarily in research and epidemiological studies
• Cannot distinguish active from past infection

Treatment and Management

Antifungal Therapy

No completely satisfactory treatment exists, but several approaches have shown limited success:

Supportive and Surgical Treatment

• Surgical debridement: Excision of localized lesions combined with antifungal therapy
• Topical treatment: 7% tincture of iodine, povidone-iodine, potassium permanganate
• Wound care: Regular cleaning, drainage of abscesses, fly control
• Antibiotics: For secondary bacterial infections

Treatment Challenges

Treatment limitations include:

• High cost and limited availability of effective antifungals
• Long treatment courses required (weeks to months)
• High recurrence rates even with treatment
• Poor prognosis in advanced cases
• Treatment often not permitted in areas where disease is notifiable

Prevention and Control

Individual Animal Management

• Wound prevention: Proper harness fitting, regular equipment inspection, prompt wound treatment
• Hygiene practices: Regular grooming with clean equipment, disinfection of shared tools
• Fly control: Insect repellents, environmental management, treatment of wounds
• Nutrition: Adequate nutrition to maintain immune function

Population Control Strategies

• Surveillance: Regular screening of equid populations in endemic areas
• Isolation: Quarantine of affected animals, restrict movement from endemic areas
• Environmental management: Disinfection of contaminated areas, proper carcass disposal
• Education: Owner education on disease recognition and prevention

Vaccination

Experimental vaccines have been developed but are not commercially available:

• Live attenuated vaccine: Shown promise in experimental studies
• Killed formalin vaccine: Limited efficacy reported
• Challenges: Cost of production, limited market in endemic areas

Prognosis and Complications

Disease Progression

Disease course varies significantly:

• Mild cases: May recover spontaneously with development of immunity
• Moderate cases: Chronic progression over months to years
• Severe cases: Extensive lesions, systemic involvement, debilitation

Complications

• Secondary infections: Bacterial superinfection of ulcerated lesions
• Lameness: Limb involvement leading to functional impairment
• Lymphatic obstruction: Chronic fibrosis leading to lymphedema
• Systemic involvement: Pulmonary lesions, weight loss, cachexia

Economic and Welfare Impact

Significant impact on working equids and their owners:

• Reduced work capacity and income loss for owners
• High treatment costs with poor success rates
• Animal welfare concerns due to chronic pain and debilitation
• Social stigma associated with foul-smelling discharge